Publications by authors named "L F Veenstra"
Background: One-third of patients undergoing TAVR have a concomitant indication for oral anticoagulation. The impact of continuation as compared to interruption of oral anticoagulation during TAVR on health-related quality of life is unknown.
Aims: To investigate the impact of continuation as compared to interruption of oral anticoagulation on health-related quality of life.
Article Synopsis
- Transcatheter aortic valve implantation (TAVI) via transfemoral access is becoming more common in treating aortic valve disease, though access-related vascular complications still affect about 10% of procedures.
- This study analyzed patients from Dutch and German hospitals who underwent TF-TAVI between 2017 and 2021, focusing on those who had occlusive complications (OC) versus hemorrhagic complications (HC) requiring further intervention.
- Results showed that patients with OC had significantly smaller arterial diameters compared to those with HC, while those with HC had a higher tortuosity index, highlighting the need for careful preoperative imaging to tailor prevention strategies.
Article Synopsis
- * In a trial with 858 patients, results showed no significant difference in major complications between those who continued anticoagulation (16.5% experienced primary outcomes) and those who interrupted it (14.8%).
- * Continuation of anticoagulation led to higher incidences of major bleeding (31.1% vs. 21.3%), suggesting that interrupting anticoagulation is safer in this patient population undergoing TAVI.
Objectives: The use of cerebral embolic protection (CEP) during transcatheter aortic valve implantation (TAVI) has been studied in several randomised trials. We aimed to perform a systematic review and Bayesian meta-analysis of randomised CEP trials, focusing on a clinically relevant reduction in disabling stroke.
Methods: A systematic search was applied to three electronic databases, including trials that randomised TAVI patients to CEP versus standard treatment.
Background: The safety of administration of tirofiban, a platelet glycoprotein IIb/IIIa inhibitor, followed by a clopidogrel loading dose in clopidogrel-naïve patients undergoing ad-hoc percutaneous coronary intervention (PCI) is not yet clear.
Methods: In a retrospective observational cohort analysis, clopidogrel-naïve patients undergoing ad-hoc PCI who received a high-dose bolus of tirofiban (25 μg/kg) followed by a 600-mg clopidogrel loading dose (group 1) were compared with patients undergoing elective PCI who were pretreated with clopidogrel (group 2), between September 2014 and October 2021. The primary outcome was major adverse cardiovascular events (MACE) defined as the composite of death, myocardial infarction, stroke, target-lesion revascularisation and bleeding at 30 days.